ARS Pharmaceuticals, Inc. Other Noncash Income (Expense)
ARS Pharmaceuticals, Inc. (SPRY) reported Other Noncash Income (Expense) of -$2.33 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was -$2.09M.
- ARS Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was -$245.00K, a 6225.00% decline year-over-year.
- ARS Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was -$151.00K.
- ARS Pharmaceuticals, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was $2.07M.
- ARS Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2025 was -$337.00K.
- ARS Pharmaceuticals, Inc. other noncash income (expense) for fiscal 2024 was $0.00.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.33M 10-Q · filed 2026-08-13 | -$2.48M derived: sum of 3 quarters · filed 2026-08-13 | -$416.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$245.00K 10-Q · filed 2026-05-15 | -$396.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.67M derived: sum of 3 quarters · filed 2026-05-15 | -$586.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$151.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.92M derived: sum of 2 quarters · filed 2026-03-09 | -$341.00K derived: sum of 3 quarters · filed 2026-08-13 | -$337.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$190.00K derived: sum of 2 quarters · filed 2026-08-13 | -$186.00K 10-Q · filed 2025-11-10 | -$186.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$2.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$2.25M 10-Q · filed 2026-08-13 | -$2.25M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-03-31 | $4.00K 10-Q · filed 2026-05-15 | $4.00K derived: sum of 2 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $0.00 10-K · filed 2026-03-09 | ||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |